- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 271/10 - 1,3,4-OxadiazolesHydrogenated 1,3,4-oxadiazoles
Patent holdings for IPC class C07D 271/10
Total number of patents in this class: 443
10-year publication summary
|
36
|
46
|
42
|
32
|
36
|
27
|
24
|
22
|
20
|
7
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Chong Kun Dang Pharmaceutical Corp. | 228 |
23 |
| Denali Therapeutics Inc. | 235 |
10 |
| Merck Sharp & Dohme LLC | 3724 |
10 |
| Modernatx, Inc. | 1249 |
9 |
| Reata Pharmaceuticals, Inc. | 121 |
9 |
| Abbvie Inc. | 1783 |
8 |
| Shionogi & Co., Ltd. | 879 |
8 |
| Calico Life Sciences LLC | 92 |
8 |
| AstraZeneca AB | 2934 |
7 |
| Takeda Pharmaceutical Company Limited | 2700 |
7 |
| Novartis AG | 11042 |
6 |
| Merck Patent GmbH | 5825 |
6 |
| SK Biopharmaceuticals Co., Ltd. | 259 |
6 |
| Ikena Oncology, Inc. | 61 |
6 |
| Bayer Cropscience AG | 2084 |
5 |
| AstraZeneca UK Limited | 667 |
4 |
| Boehringer Ingelheim International GmbH | 4732 |
4 |
| Janssen Pharmaceutica N.V. | 3436 |
4 |
| Allergan, Inc. | 2372 |
4 |
| The Arizona Board of Regents on Behalf of the University of Arizona | 2121 |
4 |
| Other owners | 295 |